1-4 of 4
John T. Isaacs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer

Mannan Nouri, Andreas Varkaris, Maya Ridinger, Susan L. Dalrymple, Christopher M. Dennehy, John T. Isaacs, David J. Einstein, W.N. Brennen, Steven P. Balk
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (10): 1404–1417.
https://doi.org/10.1158/1535-7163.MCT-23-0933
Published: 01 October 2024
View article titled, AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer
Open the PDF for AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

Oliver C. Rogers, Lizamma Antony, Oren Levy, Nitin Joshi, Brian W. Simons, Susan L. Dalrymple, D. Marc Rosen, Andrew Pickering, Haoyue Lan, Heidi Kuang, Sudhir H. Ranganath, Lei Zheng, Jeffrey M. Karp, S. Peter Howard, Samuel R. Denmeade, John T. Isaacs, W. Nathaniel Brennen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (11): 2353–2362.
https://doi.org/10.1158/1535-7163.MCT-20-0227
Published: 03 November 2020
View article titled, Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
Open the PDF for Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy

W. Nathaniel Brennen, John T. Isaacs, Samuel R. Denmeade
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 257–266.
https://doi.org/10.1158/1535-7163.MCT-11-0340
Published: 08 February 2012
View article titled, Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy
Open the PDF for Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy in another window
Journal Articles

Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells

Donald J. Vander Griend, Lizamma Antony, Susan L. Dalrymple, Yi Xu, S. Brogger Christensen, Samuel R. Denmeade, John T. Isaacs
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (5): 1340–1349.
https://doi.org/10.1158/1535-7163.MCT-08-1136
Published: 13 May 2009
View article titled, Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells
Open the PDF for Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells in another window